Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fix...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 682 0917

Website: amylyx.com

Address:

43 Thorndike Street, Cambridge, United States

SilentBull69 Dec. 25 at 10:07 PM

$NCLH $CCL $AMLX $JBLU Happy Birthday JESUS And happy holidays to all good people… And to those out there, who spend your time thinking of nothing but yourselves …being greedy, and could care less about helping other people breathe easier because you have lived. ……I hope you rethink your lives because our lives on earth are so short … And I hope those of you I’m talking about find yourselves one day opening the book of Proverbs ……to reconsider how you have lived your lives ..so that you may begin to think of others instead of just yourselves…….do it for the sake of your family ..your children, ..their children, and all virtuous people who walk this earth . 😌✌️❤️

0 · Reply

FauvistFinance Dec. 25 at 11:47 AM

$AMLX Capital stewardship is becoming the defining attribute for how this story is priced. Progress needs to be observable in both leading indicators and reported metrics. Credibility will build only through repeated confirmation across multiple cycles. Risk remains manageable if management converts plans into consistent outputs.

0 · Reply

LoveRetailFroth Dec. 24 at 2:55 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. M&amp;A heating up. $SANA $AMLX $NEWH $PLTY

0 · Reply

ajmore Dec. 24 at 7:59 AM

$AMLX oh yeah!👇

0 · Reply

SocioCobb Dec. 24 at 2:05 AM

$AMLX oh yeah!

0 · Reply

LoveRetailFroth Dec. 23 at 2:13 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. M&A heating up. $SANA $AMLX $NEWH $PLTY

0 · Reply

Kabita84 Dec. 23 at 1:59 AM

$AMLX one of the best bio stock 2025..people made 3 to 4× here ..all the long term investors are happy..management is pure gold ..good luck guys

2 · Reply

LoveRetailFroth Dec. 22 at 2:35 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. $SANA $AMLX $NEWH $PLTY

0 · Reply

ajmore Dec. 22 at 12:46 PM

$AMLX Index rebalance behind us, exciting action into the close. what does this mean: good news! why, the volume had passive buyers due to adjustments in the number of listed shares and the last batch of those taken part in the extra shares in September out of the way! This means that those shares are now kinda off the market in hands of passive. The volume also inidictes that Amylyx is in many etfs and indexes. pron around 25%. that was technicals. To the pipeline, we got great one with Avexitide making the right impact as more pbh sufferers want to join trial (word of mouth). Wolfram about to land too. Target 40. Happy holidays to all.

1 · Reply

Kabita84 Dec. 20 at 2:12 AM

$AMLX one of the best bio stock i have seen so far..you can make money through out the year..long live company..this company continuously make investors rich..

0 · Reply

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Dec 3, 2025, 7:53 PM EST - 22 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 28, 2025, 6:40 PM EST - 27 days ago

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Nov 13, 2025, 2:40 PM EST - 6 weeks ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Nov 6, 2025, 2:06 PM EST - 7 weeks ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 7 weeks ago

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 7 weeks ago

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Oct 30, 2025, 9:00 AM EDT - 2 months ago

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 27, 2025, 12:20 PM EDT - 2 months ago

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 16, 2025, 4:40 PM EDT - 2 months ago

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Sep 10, 2025, 12:06 AM EDT - 3 months ago

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Sep 9, 2025, 4:01 PM EDT - 3 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 8, 2025, 9:01 PM EDT - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 6:14 PM EDT - 4 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 27, 2025, 7:28 AM EDT - 4 months ago

Amylyx to stop development of rare brain disorder drug after trial failure

Aug 27, 2025, 7:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Aug 26, 2025, 9:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 7, 2025, 10:35 PM EDT - 5 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:00 AM EDT - 5 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 9:00 AM EDT - 5 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 21, 2025, 4:26 PM EDT - 5 months ago

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

Jul 14, 2025, 2:15 PM EDT - 5 months ago

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Jul 13, 2025, 5:00 PM EDT - 5 months ago

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Jul 8, 2025, 7:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Jun 24, 2025, 2:59 PM EDT - 6 months ago

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Jun 17, 2025, 10:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 15, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Jun 8, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 1, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

May 29, 2025, 10:05 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

May 27, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 12, 2025, 7:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 11, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

May 10, 2025, 11:19 AM EDT - 8 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

May 8, 2025, 7:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

May 4, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Reach Out

May 1, 2025, 9:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 30, 2025, 7:00 AM EDT - 8 months ago

Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia

Apr 9, 2025, 7:00 AM EDT - 9 months ago

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis

SilentBull69 Dec. 25 at 10:07 PM

0 · Reply

FauvistFinance Dec. 25 at 11:47 AM

0 · Reply

LoveRetailFroth Dec. 24 at 2:55 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. M&amp;A heating up. $SANA $AMLX $NEWH $PLTY

0 · Reply

ajmore Dec. 24 at 7:59 AM

$AMLX oh yeah!👇

0 · Reply

SocioCobb Dec. 24 at 2:05 AM

$AMLX oh yeah!

0 · Reply

LoveRetailFroth Dec. 23 at 2:13 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. M&A heating up. $SANA $AMLX $NEWH $PLTY

0 · Reply

Kabita84 Dec. 23 at 1:59 AM

$AMLX one of the best bio stock 2025..people made 3 to 4× here ..all the long term investors are happy..management is pure gold ..good luck guys

2 · Reply

LoveRetailFroth Dec. 22 at 2:35 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. $SANA $AMLX $NEWH $PLTY

0 · Reply

ajmore Dec. 22 at 12:46 PM

1 · Reply

Kabita84 Dec. 20 at 2:12 AM

$AMLX one of the best bio stock i have seen so far..you can make money through out the year..long live company..this company continuously make investors rich..

0 · Reply

ajmore Dec. 19 at 4:09 PM

$AMLX paper on pbh and avixetide published on october 25th, with Prof. Dawn Davis from Wisconsin Uni as co-author. It's a good read and a good reference! one of the clinics participating in phase 3 trial!

0 · Reply

LoveRetailFroth Dec. 19 at 3:04 PM

$RXRX Weakening economy low inflation means 🚀 $SANA $AMLX $NEWH $PLTY

0 · Reply

LoveRetailFroth Dec. 19 at 2:17 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. $SANA $AMLX $NEWH $PLTY

0 · Reply

LoveRetailFroth Dec. 18 at 2:29 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. $SANA $AMLX $NEWH $PLTY

0 · Reply

LoveRetailFroth Dec. 17 at 2:03 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. $SANA $AMLX $NEWH $PLTY

0 · Reply

ajmore Dec. 16 at 5:07 PM

$AMLX insiders, especially management, holding shares extremely tight.

1 · Reply

LoveRetailFroth Dec. 16 at 2:41 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. $SANA $AMLX $NEWH $PLTY

0 · Reply

ajmore Dec. 15 at 6:32 PM

$AMLX RSI 34. Its clear sold/shorted on RSI 68-69 and bought back 33-34, lets see. Its almost in oversold territory so expect cover or buyers stepping in. target >40.

1 · Reply

WycklyTrader Dec. 15 at 6:05 PM

$GOSS potential gap-fill with upcoming FDA catalyst. $ANRO / $AMLX $GME $PLUG : RVPH ...

0 · Reply

ajmore Dec. 15 at 4:49 PM

$AMLX pipeline, pipeline potential, investment all intact. at 3bln annual revenue a 40-50 share price is very reasonable.

0 · Reply

LoveRetailFroth Dec. 15 at 2:27 PM

$RXRX Good Morning ☕️ My 💎 s for 2026. $SANA $AMLX $NEWH $PLTY

0 · Reply

LoveRetailFroth Dec. 12 at 2:16 PM

$VVPR Good Morning 💎 s $RXRX $SANA $AMLX $PLTY

0 · Reply

Market Cap	1.37B
Revenue (ttm)	87.37M
Net Income (ttm)	-301.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-345.36%
Debt to Equity Ratio	0.00

Volume	671,500
Avg Vol	1,542,164
Day's Range	N/A - N/A
Shares Out	109.82M
Stochastic %K	46%
Beta	-0.34
Analysts	Strong Sell
Price Target	$20.22